| Literature DB >> 30551551 |
Xing Su1, Yueping Li1, Meng Jiang2, Jinglin Zhu2, Chunli Zheng2, Xuetong Chen3, Jun Zhou4, Yan Li5, Wei Xiao6, Yonghua Wang7.
Abstract
Non-small cell lung cancer (NSCLC) has become one of the most general malignancies in the world and has been shown to be the leading cause of cancer-related deaths. Traditional Chinese medicine (TCM) is considered to be a useful medicine for survival, and has been used in Asia for thousands of years. Hedyotis diffusa Willd (HDW) is an important folk herb that is used in clinical treatment of various cancers in various Chinese medicine prescriptions. However, its underlying mechanism of action remains unclear. Presently, we used an innovative system-pharmacology platform to systematically uncover the pharmacological mechanisms of HDW in the treatment of NSCLC from molecules, targets, and pathway levels. The results show that HDW treatment of NSCLC may activate immunity, achieve anti-inflammatory, anti-proliferative and anti-migration therapeutic effects by regulating multiple pathways. This research provides a new idea for understanding the mechanism of TCM and promotes to develop potential drugs from HDW in modern medicine.Entities:
Keywords: Antitumor; Hedyotis diffusa Willd; Non-small cell lung cancer; Systems pharmacology; Traditional Chinese medicine
Mesh：
Substances：
Year: 2018 PMID： 30551551 DOI： 10.1016/j.biopha.2018.10.162
Source DB: PubMed Journal: Biomed Pharmacother ISSN： 0753-3322 Impact factor: 6.529